
|Videos|March 29, 2021
Are Combinations the Answer in Metastatic RCC?
Author(s)Targeted Oncology
Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
T-DXd Improves PFS vs Standard of Care in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Piktor in Endometrial Cancer
4
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
5


































